InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 158402

Wednesday, 01/29/2014 1:54:14 PM

Wednesday, January 29, 2014 1:54:14 PM

Post# of 346474
I think its going to get a little easier to fill in the puzzle from here on out.

From my original post I noted that "Suzanne Ostrand-Rosenberg" was one of the 3 scientific organizers of this March 9-14 Keystone Symposia event.... but now we can connect her directly to Peregrine KOL= Dimitry Gabrilovich ... possibly Dimitry will be speaking here

Immune Evolution In Cancer (X2) - March 9-14, 2014
joint with the meeting on Inflammation, Infection and Cancer (X1)

Scientific Organizers: Suzanne Ostrand-Rosenberg, Olivera J. Finn and Lisa M. Coussens

Sponsored by Bristol-Myers Squibb Company, Genentech, Inc., OncoMed Pharmaceuticals, Inc., Roche and Vertex Pharmaceuticals Incorporated

http://www.keystonesymposia.org/14X2

---------------------------------------------------------

HIV Pathogenesis – Virus vs. Host (X4) - March 9-14, 2014
*joint with the meeting on HIV Vaccines: Adaptive Immunity and Beyond (X3)

Scientific Organizers: J. Victor Garcia-Martinez, Daria J. Hazuda and Dan R. Littman

Sponsored by Gilead Sciences, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation


http://www.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=1288



.... note how it said (joint with meeting HIV Vaccines..(X3)... well I just looked at the website and X3 takes up many hours/speakers/subjects and agreed, much of it is after market is closed.

I like how it ended though:

Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bill & Melinda Gates Foundation .and Gilead Sciences, Inc.




-----------------------------------------------------------------

... and finally.. the Dimitry and Suzanne connection...

Coordinated regulation of myeloid cells by tumours
Nature Reviews Immunology 12, 253-268 (April 2012) | doi:10.1038/nri3175

Dmitry I. Gabrilovich, Suzanne Ostrand-Rosenberg & Vincenzo Bronte

http://www.nature.com/nri/journal/v12/n4/abs/nri3175.html


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News